## Valérie Vilgrain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4104398/publications.pdf

Version: 2024-02-01

154 papers 11,625 citations

36 h-index 30848 102 g-index

158 all docs

158 docs citations

158 times ranked

11512 citing authors

#	Article	IF	CITATIONS
1	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	1.8	6,153
2	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	5.1	595
3	A Single-Center Surgical Experience of 122 Patients With Single and Multiple Hepatocellular Adenomas. Gastroenterology, 2009, 137, 1698-1705.	0.6	347
4	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology, 2011, 54, 1987-1997.	3.6	309
5	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
6	Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology, 2011, 53, 1182-1191.	3.6	180
7	Macrotrabecularâ€massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology, 2018, 68, 103-112.	3.6	159
8	Focal nodular hyperplasia. European Journal of Radiology, 2006, 58, 236-245.	1.2	132
9	A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. European Radiology, 2016, 26, 4595-4615.	2.3	126
10	Prevalence of Hepatic Hemangioma in Patients with Focal Nodular Hyperplasia: MR Imaging Analysis. Radiology, 2003, 229, 75-79.	3.6	123
11	Molecular classification of hepatocellular adenoma in clinical practice. Journal of Hepatology, 2017, 67, 1074-1083.	1.8	119
12	Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with <sup>90</sup> Y in the SARAH Study. Radiology, 2020, 296, 673-684.	3.6	117
13	Diagnosis and management of solid benign liver lesions. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 737-749.	8.2	89
14	Atrophy-Hypertrophy Complex in Patients with Cavernous Transformation of the Portal Vein: CT Evaluation. Radiology, 2006, 241, 149-155.	3.6	83
15	Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3†cm. Journal of Hepatology, 2018, 68, 715-723.	1.8	83
16	Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis. Gastrointestinal Radiology, 1990, 15, 218-222.	0.4	81
17	Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. European Radiology, 2017, 27, 1748-1759.	2.3	80
18	Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial. European Journal of Cancer, 2014, 50, 3098-3106.	1.3	69

#	Article	IF	Citations
19	Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. Hepatology International, 2020, 14, 437-453.	1.9	68
20	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. European Radiology, 2020, 30, 2293-2301.	2.3	65
21	Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. CardioVascular and Interventional Radiology, 2016, 39, 8-20.	0.9	63
22	Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France. Radiology, 2021, 298, E81-E87.	3.6	57
23	Women in radiology: gender diversity is not a metric—it is a tool for excellence. European Radiology, 2020, 30, 1644-1652.	2.3	56
24	Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Reports, 2021, 3, 100199.	2.6	55
25	Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer, 1996, 78, 1686-1692.	2.0	54
26	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. Radiology, 2017, 283, 280-292.	3.6	54
27	Imaging of benign hepatocellular lesions: Current concepts and recent updates. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 681-688.	0.7	48
28	Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. Digestive Diseases and Sciences, 2019, 64, 934-950.	1.1	46
29	Functional imaging in liver tumours. Journal of Hepatology, 2016, 65, 1017-1030.	1.8	45
30	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology, 2018, 289, 698-707.	3.6	45
31	Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdominal Radiology, 2018, 43, 1968-1977.	1.0	44
32	Pitfalls in Liver Imaging. Radiology, 2016, 278, 34-51.	3.6	43
33	Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. Journal of Hepatology, 2022, 76, 420-434.	1.8	41
34	Radioembolisation with yttriumâ€'90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials, 2014, 15, 474.	0.7	38
35	Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. European Journal of Radiology, 2017, 89, 156-162.	1.2	38
36	Liver transarterial embolizations in metastatic neuroendocrine tumors. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 459-471.	2.6	38

#	Article	IF	CITATIONS
37	Hepatocellular carcinoma: Diagnostic criteria by imaging techniques. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 795-812.	1.0	37
38	Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. Journal of Hepatology, 2016, 64, 708-716.	1.8	37
39	Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. Journal of Hepatology, 2019, 70, 1123-1132.	1.8	37
40	Hepatic hemangiomas: Factors associated with T2 shine-through effect on diffusion-weighted MR sequences. European Journal of Radiology, 2014, 83, 468-478.	1,2	36
41	Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. Hpb, 2016, 18, 684-690.	0.1	35
42	Diagnosis of Budd–Chiari syndrome. Abdominal Radiology, 2018, 43, 1896-1907.	1.0	35
43	Evaluation of liver tumour response by imaging. JHEP Reports, 2020, 2, 100100.	2.6	33
44	Imaging of Hepatic Focal Nodular Hyperplasia: Pictorial Review and Diagnostic Strategy. Seminars in Ultrasound, CT and MRI, 2016, 37, 511-524.	0.7	32
45	Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellularâ€cholangiocarcinoma. Liver International, 2019, 39, 2386-2396.	1.9	32
46	CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Cancers, 2020, 12, 3089.	1.7	32
47	Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics, 2021, 41, 1611-1631.	1.4	32
48	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transplantation, 2016, 22, 1491-1500.	1.3	31
49	Focal Nodular Hyperplasia After Treatment With Oxaliplatin: A Multiinstitutional Series of Cases Diagnosed at MRI. American Journal of Roentgenology, 2018, 210, 775-779.	1.0	31
50	Inter-reader agreement of CT features of acute mesenteric ischemia. European Journal of Radiology, 2018, 105, 87-95.	1,2	31
51	Contrast-Enhanced CT for the Diagnosis of Acute Mesenteric Ischemia. American Journal of Roentgenology, 2020, 215, 29-38.	1.0	30
52	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. Journal of Hepatology, 2022, 76, 343-352.	1.8	30
53	Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging, 2019, 19, 75.	1.2	29
54	Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Reports, 2021, 3, 100380.	2.6	29

#	Article	IF	CITATIONS
55	Cone-Beam CT Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumors: Comparison of Conventional and Dedicated-Software Analysis. Journal of Vascular and Interventional Radiology, 2016, 27, 32-38.	0.2	28
56	A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. Annals of Medicine, 2020, 52, 367-375.	1.5	28
57	Endovascular management of delayed post-pancreatectomy haemorrhage. European Radiology, 2016, 26, 3456-3465.	2.3	27
58	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with <sup>90</sup> Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2020, 61, 1736-1742.	2.8	27
59	Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Quality of Life Research, 2015, 24, 2499-2506.	1.5	26
60	Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences. Hepatology, 2018, 68, 652-662.	3.6	25
61	Gender gap in articles published in European Radiology and CardioVascular and Interventional Radiology: evolution between 2002 and 2016. European Radiology, 2020, 30, 1011-1019.	2.3	25
62	Assessment of liver ablation using cone beam computed tomography. World Journal of Gastroenterology, 2015, 21, 517.	1.4	24
63	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver International, 2015, 35, 2466-2473.	1.9	24
64	Transient excess of liver fat detected by magnetic resonance imaging in women with acute fatty liver of pregnancy. American Journal of Obstetrics and Gynecology, 2016, 214, 127-129.	0.7	22
65	Risks factors for severe pain after selective liver transarterial chemoembolization. Liver International, 2017, 37, 583-591.	1.9	21
66	Viscoelastic Parameters for Quantifying Liver Fibrosis: Three-Dimensional Multifrequency MR Elastography Study on Thin Liver Rat Slices. PLoS ONE, 2014, 9, e94679.	1,1	20
67	Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly. Journal of Magnetic Resonance Imaging, 2016, 44, 1070-1090.	1.9	19
68	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. European Radiology, 2016, 26, 3094-3101.	2.3	19
69	Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. European Radiology, 2019, 29, 3791-3801.	2.3	19
70	Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. Hpb, 2020, 22, 622-629.	0.1	19
71	New insights in the management of Hepatocellular Adenoma. Liver International, 2020, 40, 1529-1537.	1.9	18
72	Gender discrepancy in research activities during radiology residency. Insights Into Imaging, 2019, 10, 125.	1.6	18

#	Article	IF	Citations
73	Colorectal liver metastases: radiopathological correlation. Insights Into Imaging, 2020, 11, 99.	1.6	18
74	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. Radiology, 2020, 295, 361-372.	3.6	17
75	Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 305-313.	1.4	16
76	Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. Abdominal Radiology, 2020, 45, 365-372.	1.0	16
77	Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatology International, 2022, 16, 509-522.	1.9	16
78	Is magnetic resonance imaging of hepatic hemangioma any different in liver fibrosis and cirrhosis compared to normal liver?. European Journal of Radiology, 2015, 84, 816-822.	1.2	15
79	Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Reports, 2020, 2, 100147.	2.6	15
80	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. CardioVascular and Interventional Radiology, 2021, 44, 36-49.	0.9	15
81	Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. Surgery, 2016, 159, 1050-1057.	1.0	14
82	Sequential Arterial and Portal Vein Embolization in Patients with Cirrhosis and Hepatocellular Carcinoma: The Hospital Beaujon Experience. Seminars in Interventional Radiology, 2008, 25, 155-161.	0.3	13
83	CT and MR perfusion techniques to assess diffuse liver disease. Abdominal Radiology, 2020, 45, 3496-3506.	1.0	13
84	Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. Diagnostic and Interventional Imaging, 2021, 102, 735-742.	1.8	13
85	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography, 2019, 38, 191-199.	1.0	13
86	Cannabinoid receptor activation in the juvenile rat brain results in rapid biomechanical alterations: Neurovascular mechanism as a putative confounding factor. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 954-964.	2.4	12
87	Avoiding Pitfalls in the Interpretation of Gadoxetic Acid–Enhanced Magnetic Resonance Imaging. Seminars in Ultrasound, CT and MRI, 2016, 37, 561-572.	0.7	12
88	Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data. European Radiology, 2017, 27, 741-748.	2.3	12
89	Uncommon evolutions and complications of common benign liver lesions. Abdominal Radiology, 2018, 43, 2075-2096.	1.0	12
90	Targeted and non-targeted liver biopsies carry the same risk of complication. European Radiology, 2019, 29, 5772-5783.	2.3	12

#	Article	IF	Citations
91	Endovascular revascularization of acute arterial mesenteric ischemia: report of a 3-year experience from an intestinal stroke center unit. European Radiology, 2022, 32, 5606-5615.	2.3	12
92	Correlation of MR changes with doppler US measurements of blood flow in exercising normal muscle. Journal of Magnetic Resonance Imaging, 1992, 2, 645-652.	1.9	11
93	Endovascular Treatment of Arterial Complications After Liver Transplantation: Long-Term Follow-Up Evaluated on Doppler Ultrasound and Magnetic Resonance Cholangiopancreatography. CardioVascular and Interventional Radiology, 2019, 42, 381-388.	0.9	11
94	Clinical impact of a new cone beam CT angiography respiratory motion artifact reduction algorithm during hepatic intra-arterial interventions. European Radiology, 2020, 30, 163-174.	2.3	11
95	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Reports, 2020, 2, 100097.	2.6	11
96	CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria. Abdominal Radiology, 2020, 45, 2755-2763.	1.0	11
97	VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Research Protocols, 2017, 6, e17.	0.5	11
98	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	1.9	11
99	Hepatic Proliferation and Angiogenesis Markers Are Increased after Portal Deprivation in Rats: A Study of Molecular, Histological and Radiological Changes. PLoS ONE, 2015, 10, e0125493.	1.1	10
100	Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents. European Radiology, 2018, 28, 3020-3031.	2.3	10
101	The diagnostic performance of a simulated "short―gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases. European Radiology, 2021, 31, 2451-2460.	2.3	10
102	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 405-416.	0.7	10
103	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). European Journal of Cancer, 2021, 154, 46-56.	1.3	10
104	Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology, 2022, 76, 1318-1328.	3.6	10
105	Differences in healthâ€related quality of life between European and Asian patients with hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e304-e311.	0.7	9
106	Budd-Chiari syndrome. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 420-425.	0.7	9
107	Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. European Radiology, 2021, 31, 3267-3275.	2.3	9
108	Portal vein variants associated with right hepatectomy: An analysis of abdominal CT angiography with 3D reconstruction. Clinical Anatomy, 2019, 32, 328-336.	1.5	8

#	Article	IF	Citations
109	Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis. CardioVascular and Interventional Radiology, 2020, 43, 1608-1618.	0.9	8
110	Hepatocellular carcinoma surveillance with ultrasound—cost-effectiveness, high-risk populations, uptake. British Journal of Radiology, 2018, 91, 20170436.	1.0	7
111	Liver CT perfusion: which is the relevant delay that reduces radiation dose and maintains diagnostic accuracy?. European Radiology, 2019, 29, 6550-6558.	2.3	7
112	Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. JHEP Reports, 2021, 3, 100326.	2.6	7
113	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. British Journal of Surgery, 2022, 109, 455-463.	0.1	7
114	Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome. Infectious Diseases, 2020, 52, 838-840.	1.4	6
115	Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes. European Radiology, 2022, 32, 2813-2823.	2.3	6
116	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. Diagnostic and Interventional Imaging, 2022, 103, 111-120.	1.8	6
117	Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Advances in Therapy, 2022, , 1.	1.3	6
118	Safety of supramesocolic surgery in patients with portal cavernoma without portal vein decompression. Large single centre experience. Hpb, 2016, 18, 623-629.	0.1	5
119	Is magnetic resonance imaging useful for the management of patients with rectal villous adenoma? A study of 45 consecutive patients treated by transanal endoscopic microsurgery. International Journal of Colorectal Disease, 2018, 33, 1695-1701.	1.0	5
120	Hereditary hemorrhagic telangiectasia and liver involvement. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 426-432.	0.7	5
121	Quantification of Pancreas Surface Lobularity on CT: A Feasibility Study in the Normal Pancreas. Korean Journal of Radiology, 2021, 22, 1300.	1.5	5
122	Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure. American Journal of Clinical Nutrition, 2021, 113, 1343-1350.	2.2	5
123	The SVD beamformer with diverging waves: a proof-of-concept for fast aberration correction. Physics in Medicine and Biology, 2021, 66, 18LT01.	1.6	5
124	Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI. Insights Into Imaging, 2022, 13, 81.	1.6	5
125	Hepatic capsular retraction: spectrum of diagnosis at MRI. Acta Radiologica Short Reports, 2014, 3, 204798161454566.	0.7	4
126	Combined Transhepatic Portal Venous and Transarterial Treatment of Superior Mesenteric Arteriovenous Fistula in a Patient with Cirrhosis. Journal of Vascular and Interventional Radiology, 2015, 26, 601-603.	0.2	4

#	Article	IF	CITATIONS
127	Optimal visualization of focal nodular hyperplasia: quantitative and qualitative evaluation of single and multiphasic arterial phase acquisition at 1.5ÂT MR imaging. Abdominal Radiology, 2016, 41, 990-1000.	1.0	4
128	Development of Collateral Pathways in Tumor Obstruction of Confluence of the Hepatic Veins: Neither Fortuitous nor Innocuous. Journal of the American College of Surgeons, 2016, 223, 595-601.	0.2	4
129	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	1.1	4
130	MRI is useful to suggest and exclude malignancy in mucinous cystic neoplasms of the pancreas. European Radiology, 2022, 32, 1297-1307.	2.3	4
131	Gallbladder Volvulus. Radiology, 2021, 301, 43-43.	3.6	3
132	Laparoscopic-assisted liver transplantation: A realistic perspective. American Journal of Transplantation, 2022, 22, 3069-3077.	2.6	3
133	Tumour detection in the liver: role of multidetector-row CT. European Radiology, Supplement, 2005, 15, d85-d88.	1.8	2
134	Clinical studies in hepatocellular carcinoma. Future Oncology, 2014, 10, 13-16.	1.1	2
135	Hepatocellular Carcinoma With Osseous Metaplasia and Bone Marrow Elements. Clinical Gastroenterology and Hepatology, 2015, 13, e26-e27.	2.4	2
136	Indication of Percutaneous Microwave Ablation for the Treatment of Hepatic Adenomas: Squaring the Circle. Journal of Vascular and Interventional Radiology, 2016, 27, 932-933.	0.2	2
137	Impact of Liver Diseases on HeartÂandÂLungs. JACC: Cardiovascular Imaging, 2019, 12, 2071-2075.	2.3	2
138	Rare Solid Tumor of the Exocrine Pancreas: A Pictorial Review. Seminars in Ultrasound, CT and MRI, 2019, 40, 483-499.	0.7	2
139	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101731.	0.7	2
140	Women in focus: advice from the front lines on how to enable well-being and build resilience. Insights Into Imaging, 2020, $11,55$ .	1.6	2
141	Steatosis Alters the Activity of Hepatocyte Membrane Transporters in Obese Rats. Cells, 2021, 10, 2733.	1.8	2
142	Monocrotaline Toxicity Alters the Function of Hepatocyte Membrane Transporters in Rats. International Journal of Molecular Sciences, 2022, 23, 7928.	1.8	2
143	The Liver Halo Sign after Tumor Ablation. Journal of Vascular and Interventional Radiology, 2014, 25, 1641-1643.	0.2	1
144	A Rare Cause of Pancreatitis. Gastroenterology, 2017, 153, 655-656.	0.6	1

#	Article	IF	CITATIONS
145	Imaging of liver tumours: What's new?. Liver International, 2020, 40, 154-159.	1.9	1
146	Segmental Arterial Mediolysis. Radiology, 2022, 302, 515-515.	3.6	1
147	Re: "Radiofrequency Ablation of Hepatic Cysts: Evaluation of Therapeutic Efficacy― Journal of Vascular and Interventional Radiology, 2014, 25, 808.	0.2	O
148	Shear-wave Elastography for the Noninvasive Diagnosis of Focal Liver Lesions: It Always Starts with the Clinical Context. Radiology, 2015, 276, 928-929.	3.6	0
149	Response: Transient liver modifications associated with abdominal sepsis are various and underestimated. European Radiology, 2016, 26, 4327-4328.	2.3	0
150	Multiparametric magnetic resonance imaging in patients with chronic liver disease: are we there yet?. Liver International, 2016, 36, 631-633.	1.9	0
151	Letter to the Editor re: Should fat in the radiofrequency ablation zone of hepatocellular adenomas raise suspicion for residual tumour?. European Radiology, 2017, 27, 2235-2236.	2.3	0
152	Reply to "Oxaliplatin-Induced Liver Changes on Gadoxetate Disodium–Enhanced Liver MRI― American Journal of Roentgenology, 2018, 211, W134-W134.	1.0	0
153	Imaging of disseminated actinomycosis. Diagnostic and Interventional Imaging, 2021, 102, 399-401.	1.8	0
154	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2022, 14, 2634.	1.7	0